Sartorius and Repligen collaborate on perfusion enabled bioreactors

Wax Selection – Leaders in Pharma, Biotech & MedTech Recruitment

Designing the bioreactors to control cell growth, fluid management and cell retention to ultimately simplify the development and cGMP manufacture of biological drugs.

Sartorius Stedim Biotech (SSB) and Repligen Corporation have partnered to integrate Repligen’s XCell ATF cell retention control technology into SSB’s BIOSTAT STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors.

SSB is an international supplier for the biopharmaceutical industry and Repligen Corporation is a global life sciences company focused on bioprocessing technologies.

Christine Gebski, VP of Product Management at Repligen, said: “We are excited to partner with SSB, a global innovator in bioreactor technology. The integration of our market-leading XCell ATF control technology with SSB’s high-performance bioreactors offers a simplified perfusion-enabled bioreactor solution for end users to develop cell culture processes more quickly and implement perfusion more efficiently.”

As a result of this collaboration, end users will stand to benefit from a single control system for 50–2000 litre bioreactors used in perfusion cell culture applications. This single interface is designed to control cell growth, fluid management and cell retention in continuous and intensified bioprocessing and ultimately, simplify the development and cGMP manufacture of biological drugs.

Through the partnership, SSB and Repligen will further collaborate to equip SSB’s recently launched ambr 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo hollow fibre filter technology.

The bioreactor system will be sold by SSB as a complete single-use assembly. This optimal design conserves the hollow fibre filter technology across scales, enabling customers to fast track development and scale up their cell culture perfusion processes.

“Sartorius Stedim Biotech has continuously expanded its integrated upstream portfolio for the past years with a focus on robust and scalable, automated single-use solutions, optimized for high-cell-density applications. The collaboration with Repligen will result in easy-to-implement, high-performance and perfusion-ready bioreactors ranging from process development to commercial manufacturing scale,” commented Stefan Schlack, Head of Marketing at SSB.

SOURCE: www.manufacturingchemist.com/news